2025-11-11T13:11:11-06:00 2024-12-31 333709623 COHNREZNICK ADVISORY LLC 7501 WISCONSIN AVENUE SUITE 400E BETHESDA MD 20814 990 2024-01-01 311667995 CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY CONQ 5714831700 2318 MILL ROAD SUITE 800 ALEXANDRIA VA 22314 MELINDA O'LEARY CFO 5714831700 2025-11-07 1 1 ZACHARY SEGAL P01511850 3016529100 2025-10-23 2024 2025-03-06 01:10:19Z CONQUER CANCER & CONQUER CANCER FDTN NANCY DALY MS MPH 2318 MILL ROAD SUITE 800 ALEXANDRIA VA 22314 44231076 0 X WWW.CONQUER.ORG X 1999 VA TO ACCELERATE BREAKTHROUGHS IN LIFESAVING RESEARCH AND EMPOWER PEOPLE EVERYWHERE TO CONQUER CANCER. 21 20 0 300 0 0 34540916 37343075 1328134 364257 3429291 3994373 -201634 -266086 39096707 41435619 19433873 18795488 0 0 0 0 358751 301139 9904103 13783056 15684793 33575680 34781420 5521027 6654199 110051603 120676056 13025732 12476623 97025871 108199433 X CONQUER CANCER FUNDS RESEARCH FOR EVERY TYPE OF CANCER TO BENEFIT EVERY PATIENT, EVERYWHERE. WORKING IN COLLABORATION WITH A GLOBAL NETWORK OF TOP SCIENTISTS AND CLINICIANS, AND LEADING ADVOCACY AND RESEARCH ORGANIZATIONS, CONQUER CANCER DRAWS (CONTINUED IN SCHEDULE O) ON THE PASSION AND EXPERTISE OF THE CANCER PROFESSIONALS WHO ARE MEMBERS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO). CONQUER CANCER WORKS TO HELP CREATE A WORLD WHERE CANCER IS PREVENTED OR CURED AND EVERY SURVIVOR IS HEALTHY. 0 0 15850256 11835076 364257 SEE SCHEDULE O:RESEARCH: RESEARCH IS HOW WE CONQUER CANCER. IT MEANS EVERYTHING, FROM UNDERSTANDING HOW CANCER IMPACTS CERTAIN PEOPLE TO FINDING GROUNDBREAKING NEW WAYS TO TREAT CANCER. THE CONQUER CANCER GRANTS & AWARDS PROGRAM HAS BEEN RECOGNIZING EXCELLENCE IN CLINICAL RESEARCH, QUALITY CARE, AND TEACHING IN THE FIELD OF ONCOLOGY SINCE 1984, WHEN THE PROGRAM ORIGINALLY BEGAN UNDER THE PURVIEW OF ASCO. CONQUER CANCER FUNDS THE ENTIRE SPECTRUM OF RESEARCH ACTIVITIES RELATED TO CANCER PREVENTION, SCREENING, TREATMENT, AND OUTCOMES RESEARCH IN ALL CANCER TYPES, AND SUPPORTS PROGRESS BY FUNDING CANCER RESEARCHERS AT ALL STAGES OF THEIR CAREERS, ENABLING ONCOLOGY'S BEST AND BRIGHTEST TO PURSUE PROMISING RESEARCH. CONQUER CANCER AND ASCO HAVE FUNDED MORE THAN $191 MILLION TO SUPPORT GRANTS & AWARDS TO OVER 9,300 RECIPIENTS IN 90 COUNTRIES. HIGHLIGHTS OF 2024 RESEARCH ACTIVITIES AND ACCOMPLISHMENTS INCLUDE: *ADVANCED CLINICAL RESEARCH AWARD (ACRA): $1,350,000 PROVIDED THREE (3) THREE-YEAR AWARDS TO PHYSICIAN-SCIENTISTS COMMITTED TO SUPPORT CLINICAL CANCER RESEARCH WITH A PATIENT-ORIENTED FOCUS. AWARDS SUPPORTED FOCUSED ON BREAST CANCER RESEARCH. *CAREER DEVELOPMENT AWARD (CDA): $4,200,000 PROVIDED TWENTY-ONE (21) THREE-YEAR AWARDS INTENDED TO SUPPORT CLINICAL RESEARCH OF CLINICAL INVESTIGATORS WHO HAVE RECEIVED THEIR INITIAL FACULTY APPOINTMENTS AND ARE ESTABLISHING INDEPENDENT CLINICAL CANCER RESEARCH PROGRAMS. *YOUNG INVESTIGATOR AWARD (YIA): $4,560,000 PROVIDED NINETY-ONE (91) ONE-YEAR AWARDS DESIGNED TO ENCOURAGE AND PROMOTE HIGH-QUALITY RESEARCH IN CLINICAL ONCOLOGY BY SUPPORTING THE RESEARCH OF PROMISING INVESTIGATORS DURING THE TRANSITION FROM A FELLOWSHIP PROGRAM TO A FACULTY APPOINTMENT. *GLOBAL ONCOLOGY YOUNG INVESTIGATOR AWARD: $300,000 PROVIDED FIVE (6) ONE-YEAR AWARDS TO EARLY-CAREER INVESTIGATORS TO SUPPORT RESEARCH IN GLOBAL ONCOLOGY AND TO DEVELOP THE NEXT GENERATION OF RESEARCHERS TO ADDRESS GLOBAL HEALTH NEEDS. THIS IS A MENTORED AWARD AND THE RESEARCH PROJECT IS CONDUCTED UNDER THE GUIDANCE OF A SCIENTIFIC MENTOR. *INTERNATIONAL INNOVATION GRANT: $39,500 PROVIDED TWO (2) ONE-YEAR AWARDS IN SUPPORT OF NOVEL AND INNOVATIVE PROJECTS THAT HAVE THE POTENTIAL TO REDUCE THE CANCER BURDEN IN LOCAL COMMUNITIES, WHILE ALSO BEING POTENTIALLY TRANSFERRABLE TO OTHER LOW- OR MIDDLE- INCOME SETTINGS. *LONG-TERM INTERNATIONAL FELLOWSHIP: $115,000 PROVIDED ONE (1) ONE YEAR GRANT WHICHENABLES AN EARLY CAREER MEMBER ONCOLOGIST IN A LOW TO MIDDLE INCOME COUNTRY AND THEIR MENTOR IN THE UNITED STATES OR CANADA TO EXTEND THE COLLABORATION THROUGH A RESEARCH FELLOWSHIP AT THE MENTOR'S INSTITUTION.THROUGH ITS EVERYGRANT PROGRAM, CONQUER CANCER UTILIZES ITS SKILLS AND EXPERTISE IN GRANTS ADMINISTRATION AND PROGRAM MANAGEMENT TO COLLABORATE WITH OTHER ORGANIZATIONS TO DEVELOP AND DELIVER PROGRAMS THAT MAKE A DIFFERENCE TO CANCER CARE TEAMS AND PATIENTS EVERYWHERE. 6121671 5914045 SEE SCHEDULE O:PROFESSIONAL EDUCATION: CONQUER CANCER SUPPORTS THE EFFORTS OF ASCO TO PROVIDE EDUCATION PROGRAMS IN THE US AND INTERNATIONALLY WHICH PROMOTE THE VITAL EXCHANGE OF IDEAS AND LATEST DEVELOPMENTS THAT LEAD TO WORLD-CLASS CARE, EVERYWHERE. FUNDS FROM CONQUER CANCER ARE USED TO SUPPORT ASCO'S SCIENTIFIC AND EDUCATIONAL PROGRAMS THROUGH BOTH MEETINGS AND ELECTRONIC EDUCATION OFFERINGS. HIGHLIGHTS OF THE PROFESSIONAL EDUCATIONAL AND SCIENTIFIC PROGRAMS SUPPORTED BY CONQUER CANCER AND PRESENTED TO THE PUBLIC IN 2024 INCLUDE THE FOLLOWING: * ASCO ANNUAL MEETING: THE ASCO ANNUAL MEETING IS A GLOBAL GATHERING OF MORE THAN 44,000 PARTICIPANTS WHERE ONCOLOGY PROFESSIONALS CONNECT, COLLABORATE, AND INSPIRE. THE MEETING IS KNOWN FOR ADVANCING THE ONCOLOGY FIELD AND OFFERS AN EXPERIENCE UNLIKE ANY OTHER, BRINGING TOGETHER THE BEST MINDS TO SHAPE THE FUTURE OF CANCER CARE. *GASTROINTESTINAL CANCERS (GI) SYMPOSIUM: THIS IS ONE OF THE PREMIER MULTIDISCIPLINARY GI CANCER SCIENTIFIC AND EDUCATIONAL MEETINGS. THE SYMPOSIUM OFFERS THE LATEST INNOVATIVE SCIENCE, SOLUTION-FOCUSED STRATEGIES, AND MULTIDISCIPLINARY APPROACHES IN GI CANCER TREATMENT, RESEARCH, AND CARE. *GENITOURINARY CANCERS (GU) SYMPOSIUM: THE GU SYMPOSIUM OFFERS AN UNPARALLELED MEETING EXPERIENCE THAT HELPS ATTENDEES TO REMAIN AT THE FOREFRONT OF ADVANCES IN GU CANCER CARE. AS ONE OF THE ONLY WORLD-CLASS SYMPOSIA OF ITS KIND, THE SYMPOSIUM UNVEILS PARADIGM-SHIFTING DISCOVERIES AND FOSTERS COLLABORATIONS THAT WILL TRANSFORM GU CANCER CARE. 1264857 1046367 SEE SCHEDULE O:*QUALITY CARE SYMPOSIUM: THIS PREMIER MEETING FOCUSES ON IMPROVING THE QUALITY, SAFETY, AND EFFICIENCY OF CANCER CARE DELIVERY, BRINGING TOGETHER THE ENTIRE CLINICAL CARE TEAM TO EXPLORE THE LATEST ADVANCEMENTS IN QUALITY IMPROVEMENT THROUGH RESEARCH, EDUCATION, AND DISCUSSIONS. *MERIT AND ABSTRACT AWARDS: $294,000 PROVIDED TWO HUNDRED EIGHTY-NINE (289) MERIT AWARDS TO PROMOTE CLINICAL RESEARCH BY AWARDING YOUNG SCIENTISTS WHOSE RESEARCH IS ADDRESSED IN HIGH QUALITY ABSTRACTS SUBMITTED TO ASCO MEETINGS WITH AN OPPORTUNITY TO PRESENT THEIR RESEARCH AT ASCO SCIENTIFIC MEETINGS AND DISEASE SPECIFIC SYMPOSIA. $40,000 PROVIDED FORTY (40) ABSTRACT AWARDS TO THE PRESENTING AUTHORS OF THE 40 HIGHEST-RATED ABSTRACTS SELECTED FOR PRESENTATION AT THE ASCO BREAKTHROUGH MEETING THAT FOCUSES ON HOW INNOVATIONS IN TECHNOLOGY CREATE BOTH SOLUTIONS AND CHALLENGES IN PATIENT CARE AND RESEARCH. 23236784 1 1 0 0 0 0 0 0 0 1 0 0 0 0 1 1 1 1 0 0 1 1 1 1 1 0 0 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 1 0 1 152 0 1 0 0 0 0 0 0 1 1 0 0 0 0 0 0 X 21 20 0 0 0 0 0 1 1 1 1 0 0 1 1 1 1 1 1 0 0 0 AL AR CA CT FL GA HI IL KS KY MD MA MI MN MS NH NJ NM NY ND OR PA RI SC TN UT VI WV WI X X MELINDA O'LEARY 5714831300 2318 MILL ROAD STE 800 ALEXANDRIA VA 22314 CLIFFORD A HUDIS MD EXECUTIVE VICE CHAIR 6.50 31.00 X X 0 1114041 25875 HOWARD A BURRIS III MD BOARD CHAIR 1.00 2.00 X X 0 0 0 ALEXANDER W CASDIN TREASURER 1.00 X X 0 0 0 AMY C PETERSON MD SECRETARY 1.00 X X 0 0 0 TERESA ALONSO THOMPSON BOARD MEMBER 1.00 X 0 0 0 KATHRYN BEAL MD BOARD MEMBER 1.00 X 0 0 0 WILLIAM BEHNKE BOARD MEMBER 1.00 X 0 0 0 RICCARDO BRAGLIA BOARD MEMBER 1.00 X 0 0 0 OTIS BRAWLEY MD BOARD MEMBER 1.00 X 0 0 0 LAWRENCE H EINHORN MD BOARD MEMBER 1.00 X 0 0 0 JASMINE FERRER MD BOARD MEMBER 1.00 X 0 0 0 RAJ MANTENA RPH BOARD MEMBER 1.00 X 0 0 0 THOMAS A MARSLAND MD BOARD MEMBER 1.00 X 0 0 0 ROBERT J MAYER MD BOARD MEMBER 1.00 X 0 0 0 GERALD J MCDOUGALL BOARD MEMBER 1.00 X 0 0 0 ANNE MOORE MD BOARD MEMBER 1.00 X 0 0 0 STEVEN T ROSEN MD BOARD MEMBER 1.00 X 0 0 0 ALEXANDRA SHAPIRO BOARD MEMBER 1.00 X 0 0 0 SANDRA SWAIN MD BOARD MEMBER 1.00 X 0 0 0 MARGARET A TEMPERO MD BOARD MEMBER 1.00 X 0 0 0 DEANNA B VAN GESTEL BOARD MEMBER 1.00 X 0 0 0 MELINDA O'LEARY CFO (PARTIAL YEAR) 1.00 36.50 X 0 259970 24887 NANCY DALY MS MPH CEO & EXECUTIVE VP 36.50 1.00 X 0 536218 47217 0 1910229 97979 0 0 1 0 RKD GROUP LLC 2701 N DALLAS PKWY STE 650 PLANO TX 75093 PRO FUNDRAISING SERVICES 176389 THE HARRINGTON AGENCY 329 DICKINSON AVENUE SWARTHMORE PA 19081 PRO FUNDRAISING SERVICES 124750 2 3133 1378500 911890 3770000 31279552 1284859 37343075 GRANTS EXPERTISE 900099 364257 364257 364257 3112850 3112850 3410894 2529371 881523 881523 881523 0 911890 266086 -266086 -266086 41435619 364257 0 3728287 17448988 17448988 396000 396000 950500 950500 10510305 2117381 1193284 7199640 178 178 63524 63524 301139 301139 70286 70286 2172406 1551194 114672 506540 30988 5402 511 25075 1056578 90799 41783 923996 1045972 77014 122975 845983 201928 141275 27132 33521 232062 205025 27037 483 270 213 66159 25638 40521 10651 10651 BAD DEBT 213201 213201 PRINTING/POSTAGE/PRODUC 2889 2889 7183 557 5975 651 34781420 23236784 1640533 9904103 5985305 4647067 10280846 15808972 25000 686 85000 122899 93675452 100096432 110051603 120676056 186512 7161076 6724249 326183 3440100 4796765 2674871 192599 13025732 12476623 X 37868738 39431103 59157133 68768330 97025871 108199433 110051603 120676056 6654199 4519363 0 X X 0 1 X 1 0 X 34795083 22059688 31125188 34540916 37343075 159863950 34795083 22059688 31125188 34540916 37343075 159863950 33815743 126048207 1592952 1980450 1978770 2573994 3112850 11239016 276883 276883 171379849 2518326 0.73550 0.74480 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 45119652 11496005 3574733 1373918 58816472 35282081 6649346 4658864 1470639 45119652 39078370 2822771 -5342139 1276921 35282081 35692561 1997125 2783059 1394375 39078370 27740161 6504115 2786765 1338480 35692561 0.00000 1.00000 0.00000 0 0 0 DUE TO ASCO 192599 192599 X 46150782 4519363 4519363 41631419 70286 -266086 -195800 41435619 34977220 266086 266086 34711134 70286 70286 34781420 PART V, LINE 4: PERMANENTLY RESTRICTED NET ASSETS OF DONOR-RESTRICTED ENDOWMENT FUNDS ARE PRESERVED, ABSENT EXPLICIT DIRECTION FROM THE DONOR. INTEREST FROM THE PERMANENTLY RESTRICTED FUNDS IS INTENDED TO FUND FUTURE RESEARCH AND/OR EDUCATIONAL AWARDS. PART X, LINE 2: CONQUER CANCER IS EXEMPT FROM FEDERAL INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE ("IRC"). IT HAS BEEN GRANTED PUBLIC CHARITY STATUS BY THE INTERNAL REVENUE SERVICE (THE "IRS") AND HAS BEEN CLASSIFIED AS OTHER THAN A PRIVATE FOUNDATION. IN 2024 AND 2023, CONQUER CANCER GENERATED NO UNRELATED BUSINESS INCOME AND ACCORDINGLY HAD RELATED BUSINESS INCOME TAX OF $0 IN 2024 AND 2023, RESPECTIVELY. CONQUER CANCER ACCOUNTS FOR UNCERTAINTY IN INCOME TAXES IN ACCORDANCE WITH THE INCOME TAX TOPIC OF THE FINANCIAL ACCOUNTING STANDARDS BOARD ACCOUNTING STANDARDS CODIFICATION ("FASB ASC"). CONQUER CANCER BELIEVES THAT IT HAS APPROPRIATE SUPPORT FOR ANY TAX POSITIONS TAKEN AND, AS SUCH, DOES NOT HAVE ANY UNCERTAIN TAX POSITIONS THAT ARE MATERIAL TO THE FINANCIAL STATEMENTS. GENERALLY, CONQUER CANCER IS NO LONGER SUBJECT TO INCOME TAX EXAMINATIONS BY THE U.S. FEDERAL, STATE OR LOCAL TAX AUTHORITIES FOR YEARS BEFORE 2021. PART XI, LINE 4B - OTHER ADJUSTMENTS: FUNDRAISING EXPENSE -266,086. PART XII, LINE 2D - OTHER ADJUSTMENTS: FUNDRAISING EXPENSE 266,086. PART V, LINES 1A-AG ENDOWMENT FUNDS ARE BASED ON GAAP AND AGREE TO THE RESTRICTED FUNDS ON THE AUDITED FINANCIAL STATEMENTS. 1 EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, 0 0 PROGRAM SERVICES AWARDS & GRANTS 105000 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 PROGRAM SERVICES AWARDS & GRANTS 133000 MIDDLE EAST AND NORTH AFRICA 0 0 PROGRAM SERVICES AWARDS & GRANTS 201000 NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES 0 0 PROGRAM SERVICES AWARDS & GRANTS 269000 SOUTH AMERICA 0 0 PROGRAM SERVICES AWARDS & GRANTS 51000 SOUTH ASIA - AFGHANISTAN, BANGLADESH, BHUTAN, INDIA, MALDIVES, NEPAL, 0 0 PROGRAM SERVICES AWARDS & GRANTS 102000 SUB-SAHARAN AFRICA - ANGOLA, BENIN, BOTSWANA, BURKINA FASO, 0 0 PROGRAM SERVICES AWARDS & GRANTS 89500 0 0 0 0 0 0 950500 0 950500 EAST ASIA AND THE PACIFIC GLOBAL ONCOLOGY YOUNG INVESTIGATOR AWARD 50000 WIRE 0 SOUTH ASIA GLOBAL ONCOLOGY YOUNG INVESTIGATOR AWARD 50000 WIRE 0 SUB-SAHARAN AFRICA INTERNATIONAL INNOVATION GRANT 19500 WIRE 0 SUB-SAHARAN AFRICA INTERNATIONAL INNOVATION GRANT 20000 WIRE 0 SOUTH AMERICA YOUNG INVESTIGATOR AWARD 50000 WIRE 0 EUROPE (INCLUDING ICELAND & GREENLAND) GLOBAL ONCOLOGY YOUNG INVESTIGATOR AWARD 50000 WIRE 0 MIDDLE EAST AND NORTH AFRICA CAREER DEVELOPMENT AWARD 200000 WIRE 0 SOUTH ASIA GLOBAL ONCOLOGY YOUNG INVESTIGATOR AWARD 50000 WIRE 0 NORTH AMERICA GLOBAL ONCOLOGY YOUNG INVESTIGATOR AWARD 50000 WIRE 0 EUROPE (INCLUDING ICELAND & GREENLAND) YOUNG INVESTIGATOR AWARD 50000 WIRE 0 SUB-SAHARAN AFRICA GLOBAL ONCOLOGY YOUNG INVESTIGATOR AWARD 50000 WIRE 0 NORTH AMERICA CAREER DEVELOPMENT AWARD 200000 WIRE 0 12 0 ANNUAL MEETING MERIT AWARD EUROPE (INCLUDING ICELAND & GREENLAND) 17 17000 WIRE ANNUAL MEETING MERIT AWARD NORTH AMERICA 13 13000 WIRE ANNUAL MEETING MERIT AWARD EAST ASIA AND THE PACIFIC 7 7000 WIRE GASTROINTESTINAL CANCERS SYMPOSIUM MERIT AWARD NORTH AMERICA 3 3000 WIRE GASTROINTESTINAL CANCERS SYMPOSIUM MERIT AWARD EUROPE (INCLUDING ICELAND & GREENLAND) 7 7000 WIRE GASTROINTESTINAL CANCERS SYMPOSIUM MERIT AWARD EAST ASIA AND THE PACIFIC 4 4000 WIRE GENITOURINARY CANCERS SYMPOSIUM MERIT AWARD NORTH AMERICA 3 3000 WIRE GENITOURINARY CANCERS SYMPOSIUM MERIT AWARD EUROPE (INCLUDING ICELAND & GREENLAND) 7 7000 WIRE GENITOURINARY CANCERS SYMPOSIUM MERIT AWARD EAST ASIA AND THE PACIFIC 1 1000 WIRE BREAKTHROUGH MERIT AWARD SOUTH ASIA 2 2000 WIRE BREAKTHROUGH MERIT AWARD MIDDLE EAST AND NORTH AFRICA 1 1000 WIRE BREAKTHROUGH MERIT AWARD EUROPE (INCLUDING ICELAND & GREENLAND) 1 1000 WIRE BREAKTHROUGH MERIT AWARD EAST ASIA AND THE PACIFIC 14 14000 WIRE BREAKTHROUGH ABSTRACT AWARD EAST ASIA AND THE PACIFIC 29 29000 WIRE BREAKTHROUGH ABSTRACT AWARD SOUTH AMERICA 1 1000 WIRE BREAKTHROUGH ABSTRACT AWARD EUROPE (INCLUDING ICELAND & GREENLAND) 1 1000 WIRE 0 0 0 0 0 0 PART I, LINE 2: CONQUER CANCER GRANTS ARE AWARDED BASED ON MERIT THROUGH A PEER-REVIEW PROCESS CONDUCTED BY MEMBERS OF CONQUER CANCER'S GRANT SELECTION COMMITTEE USING ELIGIBILITY CRITERIA ESTABLISHED FOR EACH SPECIFIC GRANT. GRANTEES ARE REQUIRED TO SIGN A GRANT AGREEMENT THAT ESTABLISHES CERTAIN REQUIREMENTS FOR THE GRANT. GRANTEES MUST REQUEST APPROVAL FOR ANY CHANGES IN THE GRANT PROJECT AND THE GRANTEE'S STATUS. GRANTEES MUST SUBMIT A FORMAL REQUEST FOR A CHANGE IN OBJECTIVES OR SCOPE AND INCLUDE JUSTIFICATION FOR THE CHANGES, WHICH IS SUBJECT TO CONQUER CANCER'S REVIEW AND APPROVAL. GRANTEES ARE REQUIRED TO NOTIFY CONQUER CANCER AND REQUEST A NO COST EXTENSION IF THERE ARE SIGNIFICANT DELAYS THAT WILL MATERIALLY AFFECT THE ABILITY TO ATTAIN THE OBJECTIVES OF THE GRANT PROJECT OR TO MEET THE PROPOSED TIME SCHEDULES. GRANTEES ARE REQUIRED TO NOTIFY CONQUER CANCER IF THEY PLAN TO LEAVE AN ORGANIZATION DURING THE COURSE OF A GRANT AND MUST SUBMIT A REQUEST FOR APPROVAL OF INSTITUTION TRANSFER OF THE GRANT BEFORE ANY TRANSFER TAKES PLACE. CHANGES OF GREATER THAN 5% OF THE TOTAL EARLY GRANT BUDGET BETWEEN OR INTO NEW BUDGET CATEGORIES ARE SUBJECT TO THE REVIEW AND APPROVAL. CONQUER CANCER REQUIRES TECHNICAL PROJECT REPORTS (PROGRESS REPORTS) AND BUDGET SUMMARIES (FINANCIAL REPORTS) FOR ALL GRANTS. UNLESS OTHERWISE SPECIFIED IN THE GRANT TERMS AND CONDITIONS, AN ANNUAL PROGRESS REPORT AND A BUDGET SUMMARY ARE REQUIRED TO BE SUBMITTED WITHIN 30 DAYS AND 60 DAYS, RESPECTIVELY, FOLLOWING THE END OF THE GRANT BUDGET PERIOD. CONQUER CANCER REVIEWS THE REPORTS AND PROVIDES THE GRANTEE AN APPROVAL NOTIFICATION. CONQUER CANCER REQUIRES A FINAL PROJECT REPORT AND BUDGET SUMMARY WITHIN 30 DAYS AND 60 DAYS, RESPECTIVELY, FOLLOWING EXPIRATION OF THE GRANT. CONQUER CANCER REVIEWS THE REPORTS AND IF APPROVED, PROVIDES THE GRANTEE AN APPROVAL NOTIFICATION. ALL UNUSED FUNDS AT THE END OF THE AWARD TERM MUST BE RETURNED. GRANTS ARE ADMINISTRATIVELY CLOSED AFTER RECEIPT OF THE FINAL PROJECT REPORT AND FINAL BUDGET SUMMARY AND AFTER CONQUER CANCER'S DETERMINATION THAT ANY OTHER ADMINISTRATIVE REQUIREMENTS IN THE GRANT HAVE BEEN MET. CONQUER CANCER RESERVES THE RIGHT TO ASK THE GRANTEE TO RETURN FUNDS THAT WERE SPENT INCONSISTENT WITH THE APPROVED BUDGET. PART I, LINE 3: THE ACCRUAL METHOD IS USED TO ACCOUNT FOR FOREIGN EXPENDITURES. X X X X X X 1 RKD GROUP LLC 2701 N DALLAS PARKWAY PLANO TX 75093 COUNSEL & MEDIA BUYS 0 372663 1130064 -757401 THE HARRINGTON AGENCY 329 DICKINSON AVENUE SWARTHMORE PA 19081 COUNSEL & MEDIA BUYS 0 347699 802946 -455247 720362 1933010 -1212648 AL AK AR CA CO CT DC FL GA HI IL KS KY LA ME MD MA MI MN MS MO NV NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI CONQUER CANCER DINNER 911890 911890 58750 207336 911890 911890 58750 207336 266086 -266086 SCHEDULE G, PART I, LINE 2B, COLUMN (V) CONQUER CANCER PAYS A RETAINER FEE FOR FUNDRAISING SERVICES, INCLUDING STRATEGY, COPY WRITING, LIST RECOMMENDATIONS, DATA ANALYSIS, ETC. 1 AMERICAN SOCIETY OF CLINICAL ONCOLOGY INC 2318 MILL RD STE 800 ALEXANDRIA VA 22314 136180380 501(C)(3) 7681670 0 CHARITABLE ASSISTANCE BAYLOR COLLEGE OF MEDICINE ONE BAYLOR PLAZA BCM 310 HOUSTON TX 77030 741613878 501(C)(3) 250000 0 YOUNG INVESTIGATOR AWARD, CAREER DEVELOPMENT AWARD BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE 1500 EAST DUARTE ROAD DUARTE CA 91010 953432210 501(C)(3) 50000 0 YOUNG INVESTIGATOR AWARD CHILDREN'S HOSPITAL OF PHILADELPHIA 2716 SOUTH STREET PHILADELPHIA PA 19146 231352166 501(C)(3) 100000 0 YOUNG INVESTIGATOR AWARD CITY OF HOPE 1500 E DUARTE ROAD DUARTE CA 91010 953435919 501(C)(3) 200000 0 CAREER DEVELOPMENT AWARD COLUMBIA UNIVERSITY 630 WEST 168TH STREET BOX 49 NEW YORK NY 10032 135598093 501(C)(3) 400000 0 YOUNG INVESTIGATOR AWARD, CAREER DEVELOPMENT AWARD DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON MA 02215 042263040 501(C)(3) 1000000 0 YOUNG INVESTIGATOR AWARD, CAREER DEVELOPMENT AWARD, ADVANCED CLINICAL RESEARCH AWARD DUKE UNIVERSITY 2200 WEST MAIN STREET SUITE 1000 DURHAM NC 27705 560532129 501(C)(3) 100000 0 YOUNG INVESTIGATOR AWARD EMORY UNIVERSITY 1599 CLIFTON ROAD 4TH FLOOR ATLANTA GA 30322 580566256 501(C)(3) 50000 0 YOUNG INVESTIGATOR AWARD FRED HUTCHINSON CANCER CENTER 1100 FAIRVIEW AVE N SEATTLE WA 98391 911935159 501(C)(3) 150000 0 YOUNG INVESTIGATOR AWARD ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE BOX 1075 NEW YORK NY 10029 136171197 501(C)(3) 50000 0 YOUNG INVESTIGATOR AWARD JOHNS HOPKINS UNIVERSITY 733 N BROADWAY STE 117 BALTIMORE MD 21205 520595110 501(C)(3) 900000 0 YOUNG INVESTIGATOR AWARD, CAREER DEVELOPMENT AWARD, ADVANCED CLINICAL RESEARCH AWARD MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 042697983 501(C)(3) 550000 0 YOUNG INVESTIGATOR AWARD, CAREER DEVELOPMENT AWARD MAYO CLINIC MINNESOTA 200 FIRST STREET SW ROCHESTER MN 559050001 416011702 501(C)(3) 450000 0 ADVANCED CLINICAL RESEARCH AWARD MEMORIAL SLOAN KETTERING CANCER CENTER 1275 YORK AVENUE NEW YORK NY 10065 131624182 501(C)(3) 1415000 0 YOUNG INVESTIGATOR AWARD, LONG-TERM INTERNATIONAL FELLOWSHIP NEW YORK UNIVERSITY SCHOOL OF MEDICINE ONE PARK AVENUE 6TH FLOOR NEW YORK NY 10016 135562308 501(C)(3) 50000 0 YOUNG INVESTIGATOR AWARD NORTHWESTERN UNIVERSITY 750 N LAKE SHORE DR RUBLOFF 7TH FLOOR CHICAGO IL 60611 362167817 501(C)(3) 200000 0 YOUNG INVESTIGATOR AWARD OHIO STATE UNIVERSITY 1960 KENNY RD COLUMBUS OH 43210 316025986 501(C)(3) 50000 0 YOUNG INVESTIGATOR AWARD OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK RD MAIL CODE L106OPAM PORTLAND OR 972393098 931176109 501(C)(3) 50000 0 YOUNG INVESTIGATOR AWARD RHODE ISLAND HOSPITAL 593 EDDY STREET PROVIDENCE RI 029034923 050258954 501(C)(3) 50000 0 YOUNG INVESTIGATOR AWARD STANFORD UNIVERSITY 455 BROADWAY ST REDWOOD CITY CA 940633126 941156365 501(C)(3) 100000 0 YOUNG INVESTIGATOR AWARD THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH 350 COMMUNITY DRIVE MANHASSETT NY 11030 112673595 501(C)(3) 300000 0 YOUNG INVESTIGATOR AWARD, CAREER DEVELOPMENT AWARD THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER 1515 HOLCOMBE BOULEVARD HOUSTON TX 770304009 746001118 501(C)(3) 850000 0 YOUNG INVESTIGATOR AWARD, CAREER DEVELOPMENT AWARD UNIVERSITY HOSPITAL OF CLEVELAND 11100 EUCLID AVENUE LAKESIDE 1400 MAILSTOP LKS 7061 CLEVELAND OH 44106 341567805 501(C)(3) 100000 0 YOUNG INVESTIGATOR AWARD UNIVERSITY OF CALIFORNIA LOS ANGELES 10889 WILSHIRE BLVD SUITE 700 BOX 951406 LOS ANGELES CA 900951406 956006143 501(C)(3) 100000 0 YOUNG INVESTIGATOR AWARD UNIVERSITY OF CALIFORNIA SAN FRANCISCO 490 ILLINOIS STREET 4TH FLOOR BOX 0962 SAN FRANCISCO CA 94143 946036493 501(C)(3) 500000 0 YOUNG INVESTIGATOR AWARD, CAREER DEVELOPMENT AWARD UNIVERSITY OF CINCINNATI 51 GOODMAN DR SUITE 530 CINCINNATI OH 45221 316000989 501(C)(3) 50000 0 YOUNG INVESTIGATOR AWARD UNIVERSITY OF COLORADO DENVER ANSCHUTZ MEDICAL CAMPUS FITZSIMONS BLDG 13001 E 17TH PLACE RM W1124 AURORA CO 80045 846000555 501(C)(3) 200000 0 CAREER DEVELOPMENT AWARD UNIVERSITY OF KANSAS 2060 W 39TH AVENUE KANSAS CITY KS 66103 481124839 501(C)(3) 100000 0 YOUNG INVESTIGATOR AWARD UNIVERSITY OF MARYLAND BALTIMORE 620 W LEXINGTON STREET 4TH FLOOR BALTIMORE MD 21201 526002033 501(C)(3) 50000 0 YOUNG INVESTIGATOR AWARD UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET 1ST FLOOR ANN ARBOR MI 481091274 386006309 501(C)(3) 50000 0 YOUNG INVESTIGATOR AWARD UNIVERSITY OF NORTH CAROLINA CHAPEL HILL 104 AIRPORT DRIVE SUITE 2200 CAMPUS BOX 1350 CHAPEL HILL NC 275991350 566001393 501(C)(3) 500000 0 YOUNG INVESTIGATOR AWARD, CAREER DEVELOPMENT AWARD UNIVERSITY OF PENNSYLVANIA 3451 WALNUT STREET 5TH FLOOR FRANKLIN BUILDING PHILADELPHIA PA 191046205 231352685 501(C)(3) 50000 0 YOUNG INVESTIGATOR AWARD UNIVERSITY OF SOUTH FLORIDA MORSANI COLLEGE OF MEDICINE 3702 SPECTRUM BLVD SUITE 165 TAMPA FL 336129445 593102112 501(C)(3) 50000 0 YOUNG INVESTIGATOR AWARD UNIVERSITY OF UTAH 201 S PRESIDENTS CIRCLE RM 210 SALT LAKE CITY UT 841128906 876000525 501(C)(3) 200000 0 CAREER DEVELOPMENT AWARD UNIVERSITY OF WASHINGTON 4333 BROOKLYN AVENUE NE SEATTLE WA 981959472 916001537 501(C)(3) 250000 0 YOUNG INVESTIGATOR AWARD, CAREER DEVELOPMENT AWARD WASHINGTON UNIVERSITY IN SAINT LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501(C)(3) 50000 0 YOUNG INVESTIGATOR AWARD WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVENUE NEW YORK NY 10065 131623978 501(C)(3) 100000 0 YOUNG INVESTIGATOR AWARD, GIANNI BONADONNA BREAST CANCER RESEARCH FELLOWSHIP YALE UNIVERSITY 25 SCIENCE PARK 3RD FLOOR NEW HAVEN CT 06511 060646973 501(C)(3) 100000 0 YOUNG INVESTIGATOR AWARD 39 0 MERIT AWARDS 178 183000 MEDICAL STUDENT ROTATION AWARDS 25 199500 ANNUAL MEETING RESEARCH AWARDS 10 13500 PART I, LINE 2: CONQUER CANCER GRANTS ARE AWARDED BASED ON MERIT THROUGH A PEER-REVIEW PROCESS CONDUCTED BY MEMBERS OF CONQUER CANCER'S GRANT SELECTION COMMITTEE USING ELIGIBILITY CRITERIA ESTABLISHED FOR EACH SPECIFIC GRANT. GRANTEES AND SPONSORING INSTITUTIONS ARE REQUIRED TO SIGN A GRANT AGREEMENT THAT ESTABLISHES CERTAIN REQUIREMENTS FOR THE GRANT. GRANTEES MUST REQUEST APPROVAL FOR ANY CHANGES IN THE GRANT PROJECT AND THE GRANTEE'S STATUS. GRANTEES MUST SUBMIT A FORMAL REQUEST FOR A CHANGE IN OBJECTIVES OR SCOPE TO CONQUER CANCER AND INCLUDE JUSTIFICATION FOR THE CHANGES, WHICH IS SUBJECT TO CONQUER CANCER'S REVIEW AND APPROVAL. GRANTEES ARE REQUIRED TO NOTIFY CONQUER CANCER AND REQUEST A NO-COST EXTENSION IF THERE ARE SIGNIFICANT DELAYS THAT WILL MATERIALLY AFFECT THE ABILITY TO ATTAIN THE OBJECTIVES OF THE GRANT PROJECT BY THE END OF THE PROJECT PERIOD OR TO MEET THE PROPOSED TIME SCHEDULES. CONQUER CANCER MAY APPROVE UP TO A MAXIMUM OF THREE NO-COST EXTENSIONS OF SIX MONTH INCREMENTS. GRANTEES ARE REQUIRED TO NOTIFY CONQUER CANCER IF THEY PLAN TO LEAVE THEIR SPONSORING INSTITUTION DURING THE COURSE OF THEIR GRANT AND MUST SUBMIT A REQUEST FOR APPROVAL OF INSTITUTION TRANSFER OF THE GRANT BEFORE ANY TRANSFER TAKES PLACE. CHANGES OF GREATER THAN 5% OF THE TOTAL YEARLY GRANT BUDGET BETWEEN OR INTO NEW BUDGET CATEGORIES ARE SUBJECT TO CONQUER CANCER'S REVIEW AND APPROVAL. CONQUER CANCER REQUIRES TECHNICAL PROJECT REPORTS (PROGRESS REPORTS) AND BUDGET SUMMARIES (EXPENDITURE REPORTS) FOR ALL GRANTS. UNLESS OTHERWISE SPECIFIED IN THE GRANT TERMS AND CONDITIONS, AN ANNUAL PROGRESS REPORT AND AN EXPENDITURE REPORT ARE REQUIRED TO BE SUBMITTED WITHIN 30 DAYS AND 60 DAYS, RESPECTIVELY, FOLLOWING THE END OF EACH GRANT BUDGET PERIOD. CONQUER CANCER REVIEWS THE REPORTS AND PROVIDES THE GRANTEE AN APPROVAL NOTIFICATION. UNLESS OTHERWISE SPECIFIED IN THE GRANT TERMS AND CONDITIONS, A FINAL PROGRESS REPORT AND A FINAL EXPENDITURE REPORT ARE REQUIRED WITHIN 30 DAYS AND 60 DAYS, RESPECTIVELY, FOLLOWING EXPIRATION OF THE GRANT. CONQUER CANCER REVIEWS THE REPORTS AND IF APPROVED, PROVIDES THE GRANTEE AN APPROVAL NOTIFICATION. ALL UNUSED FUNDS AT THE END OF THE AWARD TERM MUST BE RETURNED TO CONQUER CANCER. GRANTS ARE ADMINISTRATIVELY CLOSED AFTER RECEIPT OF THE FINAL PROGRESS REPORT, FINAL EXPENDITURE REPORT, ANY REMAINING BALANCE ON THE GRANT, AND AFTER CONQUER CANCER'S DETERMINATION THAT ANY OTHER ADMINISTRATIVE REQUIREMENTS OF THE GRANT HAVE BEEN MET. CONQUER CANCER RESERVES THE RIGHT TO ASK THE GRANTEE TO RETURN FUNDS THAT WERE SPENT INCONSISTENTLY WITH THE APPROVED BUDGET. 0 0 0 0 0 0 0 0 0 CLIFFORD A HUDIS MD EXECUTIVE VICE CHAIR 0 1101755 0 10000 0 2286 0 25875 0 0 0 1139916 0 0 NANCY DALY MS MPH CEO & EXECUTIVE VP 0 522932 0 11000 0 2286 0 25875 0 21342 0 583435 0 0 MELINDA O'LEARY CFO (PARTIAL YEAR) 0 259731 0 0 0 239 0 19616 0 5271 0 284857 0 0 PART I, LINE 3 COMPENSATION IS ESTABLISHED BY A RELATED ORGANIZATION, THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, INC. (ASCO). THE METHODS USED BY ASCO TO DETERMINE COMPENSATION ARE: COMPENSATION COMMITTEE; INDEPENDENT COMPENSATION CONSULTANT; FORMS 990 OF OTHER ORGANIZATIONS; COMPENSATION STUDY OR SURVEY; AND APPROVAL BY BOARD OR COMPENSATION COMMITTEE. X 12 1284859 FMV 0 0 1 0 PART I, COLUMN (B): THIS NUMBER REPRESENTS THE NUMBER OF CONTRIBUTIONS MADE, NOT THE NUMBER OF ITEMS CONTRIBUTED. FORM 990, PART VI, SECTION A, LINE 7A CONQUER CANCER DOES NOT HAVE MEMBERS. DIRECTORS OF CONQUER CANCER ARE APPOINTED AND SUBJECT TO REMOVAL BY THE BOARD OF DIRECTORS OF ASCO, EXCEPT FOR DIRECTORS SERVING EX-OFFICIO. FORM 990, PART VI, SECTION A, LINE 7B THE BOARD OF DIRECTORS OF CONQUER CANCER MAY VOTE TO AMEND OR REPEAL THE BYLAWS OF CONQUER CANCER, BUT THE BOARD OF DIRECTORS OF ASCO MUST APPROVE AN AMENDMENT OR REPEAL OF THE BYLAWS TO BE EFFECTIVE. CONQUER CANCER MAY NOT AMEND ITS ARTICLES OF INCORPORATION WITHOUT PROVIDING TO ASCO WRITTEN NOTICE OF THE PROPOSED AMENDMENT AT LEAST THIRTY (30) DAYS IN ADVANCE. FORM 990, PART VI, SECTION B, LINE 11B A COPY OF THE TAX RETURN, INCLUDING ALL APPLICABLE SCHEDULES, WAS PROVIDED TO THE BOARD OF DIRECTORS, CHIEF FINANCIAL OFFICER AND GENERAL COUNSEL FOR REVIEW AND COMMENT PRIOR TO ITS FILING. FORM 990, PART VI, SECTION B, LINE 12C CONQUER CANCER MAINTAINS A NUMBER OF WRITTEN CONFLICT OF INTEREST POLICIES AND STANDARDS REGARDING THE DISCLOSURE AND MANAGEMENT OF CONFLICTS OF INTEREST. THESE POLICIES AND STANDARDS COVER ALL CONQUER CANCER STAFF, DIRECTORS, OFFICERS, COMMITTEE MEMBERS, AND ANY PERSON IN A RELATIONSHIP WITH THESE INDIVIDUALS INVOLVING THE SHARING OF INCOME OR ASSETS (E.G., SPOUSE, DEPENDENT CHILDREN). UNDER CONQUER CANCER'S POLICIES, COVERED INDIVIDUALS ARE ASKED TO DISCLOSE FINANCIAL INTERESTS IN OR OTHER RELATIONSHIPS WITH ENTITIES THAT HAVE RELEVANT COMMERCIAL INTERESTS, INCLUDING EMPLOYMENT OR LEADERSHIP POSITIONS,CONSULTANT OR ADVISORY ROLES, STOCK OWNERSHIP, HONORARIA, RESEARCH FUNDING, AND SERVICE AS AN EXPERT WITNESS. COMPLETION OF A DISCLOSURE FORM IS REQUIRED AT THE INITIATION OF SERVICE, AND UPDATED ANNUALLY THEREAFTER OR WHEN ANY MATERIAL CHANGES OCCUR. CONQUER CANCER'S CONFLICT OF INTEREST POLICIES ARE INTENDED TO HELP GUIDE THE MANAGEMENT OF ACTUAL, POTENTIAL, AND PERCEIVED CONFLICTS OF INTEREST THROUGH DISCLOSURE OF FINANCIAL INTERESTS OR OTHER RELATIONSHIPS. WHERE THE NATURE AND EXTENT OF A FINANCIAL RELATIONSHIP SUGGEST DISCLOSURE IS NOT ADEQUATE TO MANAGE A REAL OR POTENTIAL CONFLICT, COVERED INDIVIDUALS ARE REQUIRED TO RECUSE THEMSELVES FROM DECISION MAKING. RECUSAL MAY BE SELF-SELECTED, OR MAY BE REQUESTED BY THE COMMITTEE CHAIR, OFFICER, OR EXECUTIVE-LEVEL STAFF MEMBERS. IN ADDITION, WHEN CONQUER CANCER IS CONTEMPLATING ENTERING INTO A TRANSACTION OR ARRANGEMENT THAT MIGHT BENEFIT THE PRIVATE INTEREST OF ANY "INTERESTED PERSON" (I.E., A CONQUER CANCER DIRECTOR, PRINCIPAL OFFICER, OR MEMBER OF A COMMITTEE WITH BOARD DELEGATED POWERS WHO HAS A DIRECT OR INDIRECT FINANCIAL INTEREST IN THE TRANSACTION), IT MUST FOLLOW A SPECIFIC PROCEDURE TO MANAGE THE CONFLICT, INCLUDING CONSIDERING ALTERNATIVE TRANSACTIONS THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15 THE CHIEF EXECUTIVE OFFICER OF CONQUER CANCER, THE EXECUTIVE VICE CHAIR OF CONQUER CANCER, AND THE CHIEF FINANCIAL OFFICER OF CONQUER CANCER SERVE AS EMPLOYEES OF ASCO. INFORMATION REGARDING THEIR COMPENSATION AND THE PROCESS FOR DETERMINING THEIR COMPENSATION, INCLUDING REVIEW AND APPROVAL BY INDEPENDENT PERSONS, COMPARABILITY DATA, AND CONTEMPORANEOUS SUBSTANTIATION OF THE DELIBERATION AND DECISION, ARE DESCRIBED IN THE IRS FORM 990 OF ASCO. CONQUER CANCER STAFF ARE EMPLOYEES OF ASCO WHO ARE LEASED TO CONQUER CANCER. APPLICABLE INFORMATION REGARDING THEIR COMPENSATION IS DESCRIBED IN THE IRS FORM 990 OF ASCO. CONQUER CANCER DOES NOT PAY COMPENSATION TO THESE INDIVIDUALS. FORM 990, PART VI, SECTION C, LINE 19 CONQUER CANCER'S GOVERNING DOCUMENTS ARE AVAILABLE TO THE PUBLIC FROM CONQUER CANCER UPON REQUEST. CONQUER CANCER'S ARTICLES OF INCORPORATION ARE ALSO AVAILABLE TO THE PUBLIC THROUGH THE VIRGINIA STATE CORPORATION COMMISSION. CONFLICT OF INTEREST POLICIES AND STANDARDS ARE POSTED ON CONQUER CANCER'S WEBSITE. THE ANNUAL REPORT OF CONQUER CANCER IS POSTED ON CONQUER CANCER'S WEBSITE AND IS AVAILABLE TO THE PUBLIC FROM CONQUER CANCER UPON REQUEST. THE AUDITED FINANCIAL STATEMENTS OF CONQUER CANCER ARE POSTED ON CONQUER CANCER'S WEBSITE. PART XII, LINE 2C THE AUDIT OVERSIGHT PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR. AMERICAN SOCIETY OF CLINICAL ONCOLOGY 2318 MILL RD SUITE 800 ALEXANDRIA VA 22314 136180380 EDUCATION NY 501(C)(3) LINE 10 N/A 0 ASCO ASSOCIATION 2318 MILL RD SUITE 800 ALEXANDRIA VA 22314 833561639 PROMOTING COMMON INTERESTS OF MEMBERS VA 501(C)(6) ASCO 0 ASCO ASSOCIATION POLITICAL ACTION COMMITTEE 2318 MILL RD SUITE 800 ALEXANDRIA VA 22314 844213157 PAC VA 527 ASCO ASSOCIATION 0 0 1 1 0 0 0 0 0 0 0 1 1 1 1 1 1 1 0 0 ASCO ASSOCIATION Q 62743 COST